Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas

Hoshino, Masami; Haraguchi, Yoshikura; Hirasawa, Hiroyuki; Sakai, Motohiro; Saegusa, Hiroshi; Hayashi, Kazushiro; Horita, Naoki; Ohsawa, Hiroyuki

doi:10.1186/cc992

Critical Care

Table 3 Criteria of disseminated intravascular coagulation (DIC) (The Ministry of Health and Welfare of Japan [28])

From: Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas

Criteria			Points
1. Underlined disease		(+)	1
		(-)	0
2. Symptom	(1) Bleeding tendency	(+)	1
		(-)	0
	(2) Symptom caused by organ dysfunction	(+)	1
		(-)	0
3. Laboratory data	(1) Serum FDP (μg/ml)	40 ≤	3
		20 ≤ < 40	2
		10 ≤ < 20	1
		10 >	0
	(2) Platelet (× 10³/μl)	50 ≥	3
		80 ≥ > 50	2
		120 ≥ > 80	1
		120	0
	(3) Plasma fibrinogen (mg/dl)	100 ≥	2
		150 ≥ > 100	1
		150 <	0
	(4) Prothrombin time/control	1.67 ≤	2
		1.25 ≤ < 1.67	1
		1.25 >	0
4. Supplemental data	(1) Detection of soluble fibrin monomer
	(2) Increase of D-dimer
	(3) Increase of thrombin-antithrombin complex
	(4) Increase of plasmin-a₂-plasmin inhibitor complex
	(5) Exacerbation of FDP, platelet, fibrinogen within several days
	(6) Improvement of data with anticoagulant therapy
Judgment^*
1. Definite DIC	(1) Patients who do not have leukemia, pernicious anemia, liver cirrhosis,	More than 7 or 6 points with
	or who are not under cancer chemotherapy	more than two of supplemental data
	(2) Patients who have leukemia, pernicious anemia, or who are	More than 4 or 3 points with
	under cancer chemotherapy points for bleeding tendency and platelet	more than two of supplemental data
	are not included
	(3) Patients who have liver cirrhosis	More than 10 or 9 points with
		more than two of supplemental data
2. Probable DIC	(1) Patients who do not have leukemia, pernicious anemia, liver cirrhosis,	6 points
	or who are not under cancer chemotherapy
	(2) Patients who have leukemia, pernicious anemia, or who are under	3 points
	cancer chemotherapy points for bleeding tendency and platelet are not included
	(3) Patients who have liver cirrhosis	9 points

^*Exclusion: this DIC criteria cannot be applied for neonates, pregnant woman, and patients with fulminant hepatitis. FDP, fibrin and fibrinogen degradation products.

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com